Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer.
about
New targets for therapy in breast cancer: farnesyltransferase inhibitors.Prenylation inhibitors stimulate both estrogen receptor alpha transcriptional activity through AF-1 and AF-2 and estrogen receptor beta transcriptional activity.Targeting the RAS oncogene.Phase II trial of tipifarnib plus neoadjuvant doxorubicin-cyclophosphamide in patients with clinical stage IIB-IIIC breast cancerA novel role of farnesylation in targeting a mitotic checkpoint protein, human Spindly, to kinetochoresPhase I and pharmacological study of the farnesyltransferase inhibitor tipifarnib (Zarnestra, R115777) in combination with gemcitabine and cisplatin in patients with advanced solid tumoursExposure-toxicity relationships for tipifarnib in cancer patientsA phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumorsPatient-reported outcomes as a component of the primary endpoint in a double-blind, placebo-controlled trial in advanced pancreatic cancer.Targeted therapies for pancreatic cancer.A phase I multicenter study of continuous oral administration of lonafarnib (SCH 66336) and intravenous gemcitabine in patients with advanced cancer.Targeting DNA replication before it starts: Cdc7 as a therapeutic target in p53-mutant breast cancers.Present and future evolution of advanced breast cancer therapy.Lipid posttranslational modifications. Farnesyl transferase inhibitors.Effect of a farnesyl transferase inhibitor (R115777) on ductal carcinoma in situ of the breast in a human xenograft model and on breast and ovarian cancer cell growth in vitro and in vivo.Promising molecular targeted therapies in breast cancerCytotoxicity of farnesyltransferase inhibitors in lymphoid cells mediated by MAPK pathway inhibition and Bim up-regulation.Farnesyltransferase inhibitors and their role in the treatment of multiple myeloma.Targeting signal transduction pathways in metastatic breast cancer: a comprehensive review.First-line endocrine treatment of breast cancer: aromatase inhibitor or antioestrogen?Molecular-targeted agents in pancreatic cancer.Novel targeted agents in the treatment of lung cancer.Population pharmacokinetics of tipifarnib in healthy subjects and adult cancer patientsReversing resistance to targeted therapy.Molecularly targeted therapies for breast cancer.A phase II trial of capecitabine in combination with the farnesyltransferase inhibitor tipifarnib in patients with anthracycline-treated and taxane-resistant metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1103).Tipifarnib: farnesyl transferase inhibition at a crossroads.Second-line treatment of postmenopausal women with advanced breast carcinoma.Lonafarnib in cancer therapy.Combination therapy with aromatase inhibitors: the next era of breast cancer treatment?Emerging drugs to replace current leaders in first-line therapy for breast cancer.Clinical activity of tipifarnib in hematologic malignancies.Neurotoxicity of biologically targeted agents in pediatric cancer trialsSmall molecule signal transduction inhibitors for the treatment of solid tumors.Development of farnesyltransferase inhibitors for clinical cancer therapy: focus on hematologic malignancies.Advances in the treatment of breast cancer.Phase II trial of the farnesyltransferase inhibitor tipifarnib plus fulvestrant in hormone receptor-positive metastatic breast cancer: New York Cancer Consortium Trial P6205.CENP-F expression is associated with poor prognosis and chromosomal instability in patients with primary breast cancerBiologic therapies for advanced pancreatic cancer.The molecular genetics of breast cancer and targeted therapy
P2860
Q24796277-EE26BB73-D95A-48B2-B719-DF1C6C9B825BQ24796687-E9A3F475-38AD-4469-970E-3DC6C548BD41Q27687198-E98F227D-141D-418F-93F1-A1265FB3DE2BQ28240692-17A85280-C4C3-4A40-A678-1944FCF3E567Q30635394-835E93E2-0204-4521-BF64-735A8503474BQ33369069-5D627E47-E6A5-4CFE-904B-F2A5F412A744Q33374647-114B38AA-0BB3-46D8-A0E7-6F590FD499FDQ33377668-EFE5BD67-9FC0-455E-A82A-4C94A22B8CEEQ33380878-5BC848FD-A25A-4D63-A18B-AD2DB2F583BEQ33899923-5A8263FF-2873-42C6-907F-E589F0AE168BQ33914284-2A063B62-F775-4932-87B5-4DF2F04500B8Q34162501-CF36E402-B12E-4C88-9DCC-29D0B4F978C6Q34274925-4149BE64-FE5A-4F68-9FDB-28F014903C84Q34651253-0C495BDD-E977-4470-8F40-3835F4A82F9BQ35012724-E4311C89-E7A7-4B92-8941-E887C29744CBQ35040295-440138F3-90EF-4C18-B75A-44E7921B7FEBQ35525553-1F4D5EA2-041C-453E-A02F-D36E6451E794Q35569466-AB09C353-DE1E-4D3E-9318-A6DDF4E223FBQ35583942-9E6603E7-83C8-4FB5-992E-8D06DA3E698EQ35622444-59362E6F-DF15-45EB-832E-EE8706FCF4DAQ35641998-E2A866D5-F77E-4051-99CD-1C08E56D300FQ35790783-E60B7062-8091-4FD8-A539-273344528104Q35827635-3D07F64E-3F14-4A92-94E4-9A18D6CC2CD6Q36028603-5E0BA77F-BD80-4CD2-9447-D35BC7E4E64BQ36108605-831567BC-509E-492E-BD79-3C8873F00C68Q36132957-79F52977-A10F-4771-9226-D91FA9399CF6Q36407429-C13C781E-10F6-435A-BCC5-D7A21D2877D2Q36448699-2759DBA6-D3EE-440E-8E5D-0F16A91D2CE1Q36491847-1CBD0A37-204E-46C6-9DD8-D50AB120D14CQ36574547-09E82112-B4AF-4AFD-8CF9-0893C2A4ED06Q36580598-06FD62F8-B44D-4D23-9C9D-3E72DE1E6F11Q36736368-3C37BA8D-3046-483C-8D31-C841A14DA099Q36766221-35052B67-F24B-4587-9D09-C6169E2126F2Q36895413-70C1A904-28CC-462C-A78A-DBCBF093BD36Q36946766-063CA9AC-D035-4AF3-93CD-E742830E3E17Q37037373-2CE14C12-9E6D-481D-BF7A-D5CE24FCF35BQ37140318-6AD422F2-D1D5-44C3-9345-33E2FADDC400Q37149363-6A8AF5AF-2D2A-46CC-97A4-C2D9ABA35DB1Q37242685-D4918402-8262-4CFF-A257-40D8105C4FD8Q37290512-A23EC7E2-08C8-484F-BD84-3785927B9FF9
P2860
Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
name
Phase II study of the efficacy ...... 77, in advanced breast cancer.
@ast
Phase II study of the efficacy ...... 77, in advanced breast cancer.
@en
type
label
Phase II study of the efficacy ...... 77, in advanced breast cancer.
@ast
Phase II study of the efficacy ...... 77, in advanced breast cancer.
@en
prefLabel
Phase II study of the efficacy ...... 77, in advanced breast cancer.
@ast
Phase II study of the efficacy ...... 77, in advanced breast cancer.
@en
P2093
P356
P1476
Phase II study of the efficacy ...... 77, in advanced breast cancer.
@en
P2093
Angela Howes
Bart Michiels
Janine Salter
Juan Jose Perez-Ruixo
Lloyd Kelland
Paul Ellis
Peter Palmer
Stephen Houston
Stephen R D Johnston
Tamas Hickish
P304
P356
10.1200/JCO.2003.10.064
P407
P577
2003-07-01T00:00:00Z